IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer

BACKGROUND: Biliary tract cancers (BTCs) are heterogenous, highly aggressive tumors that harbor a dismal prognosis for which more effective treatments are needed. The role of cancer immunotherapy in BTC remains to be characterized. The tumor microenvironment (TME) of BTC is highly immunosuppressed a...

Descripción completa

Detalles Bibliográficos
Autores principales: Hack, Stephen P., Verret, Wendy, Mulla, Sohail, Liu, Bo, Wang, Yulei, Macarulla, Teresa, Ren, Zhenggang, El-Khoueiry, Anthony B., Zhu, Andrew X.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326820/
https://www.ncbi.nlm.nih.gov/pubmed/34377158
http://dx.doi.org/10.1177/17588359211036544

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326820/
https://www.ncbi.nlm.nih.gov/pubmed/34377158
http://dx.doi.org/10.1177/17588359211036544

Ejemplares similares